University Of Leeds

Crestone announces positive Phase 2 results for CRS3123 in treating C. difficile infections (CDI), showing high clinical cure rates and lower recurrence compared to vancomycin. CRS3123, a novel drug, maintains gut microbiota, addressing urgent need for effective CDI therapy.

AI tool Optimise, trained with 2 million health records, identifies high-risk heart patients, potentially reducing heart-related deaths and NHS pressures.